Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway

Paclitaxel, a known TLR4 ligand, leads to activation of TLR4/MyD88-dependent pathway that mediates chemoresistance and tumor progression in epithelial ovarian carcinoma (EOC). Atractylenolide-I (AO-I), a novel TLR4-antagonizing agent, inhibits TLR4 signaling by interfering with the binding of LPS or...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Huang, Jian-Ming, Zhang, Guo-Nan, Shi, Yu, Zha, Xiao, Zhu, Yi, Wang, Miao-Miao, Lin, Qing, Wang, Wen, Lu, Hai-Yan, Ma, Shi-Qi, Cheng, Jia, Deng, Bi-Fang
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3899591/
https://ncbi.nlm.nih.gov/pubmed/24452475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep03840
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars